Our Researchers

Focusing on the molecular events that induce haemopoietic stem cells (HSCs) to commit and differentiate towards the B and T lymphocyte lineages.

Research goals are to improve outcomes for individuals with pancreatic cancer through the development of early detection and novel therapeutic strategies based on molecular phenotyping and the delineation and implementation of biomarkers that facilitate clinical decision-making.

CENTRE LEAD

Research in the Sutherland group focuses on the development and understanding of new organic reactions with particular emphasis on using transition metal catalysis to create new chiral molecules.

Glioblastoma is the commonest and most aggressive primary brain tumour and is often refractory to conventional cancer treatments. The ultimate aim of our research group is to improve outcomes for patients with these tumours by overcoming their inherent resistance to radiotherapy and chemotherapy.

Investigating mechanisms of central nervous system disease in childhood acute lymphoblastic leukaemia (ALL) and ways to reduce treatment related toxicity in this condition.

Improve outcomes for head and neck cancer patients by increasing treatment efficacy and reducing toxicities

Intrathoracic malignancies including lung cancer and mesothelioma.

The oncogene-induced alterations selectively required by cancer cells to maintain viability.

Control of cell polarity in prostate cancer, part the role played by ARF GTPases and the cell surface protein Podocalyxin.

The development and implementation of stratified medicine through molecular phenotyping using both tissue- and genomic-based assays.

Preclinical PET/MRI imaging of cancer using specific probes that allows non-invasive longitudinal assessment of biological processes, such as tumour metabolism, cell proliferation, angiogenesis, hypoxia and receptor dynamics.

Studying quiescent leukaemic stem cells in order to find ways to overcome resistance to chemotherapy in CML.

Study of the developmental pathways involved in normal and aberrant haemopoietic stem cells.

The significance of the FGF and ERK5 signalling pathways in prostate cancer.

Rab-coupling protein (RCP)-mediated receptor trafficking in breast cancer progression.

Understanding how aberrant signalling drives both bladder and prostate carcinogenesis.

Using transgenic models of pancreatic cancer to  determine how potential anti-cancer agents might best be evaluated in subsequent clinical trials.

CENTRE LEAD

Our research focuses mainly on:
(a) Investigating the importance of mutations found in human pancreatic tumours using mouse models.
(b) Profiling different genetic subsets of pancreatic cancer to better understand the disease and identify specific targets for therapy.
(c) Preclinical trials of targeted therapies in clinically and genetically relevant pancreatic cancer mouse models.

Manager of Glasgow Tissue Research Facility

The contribution of Rab-regulated integrin trafficking to cancer cell migration.

Mammary gland development of the mouse as a model system for mammary neoplasia.

Investigation of signal transduction mechanisms associated with the development and progression of breast, colorectal, renal and prostate cancer.

The main research interest of the Prunet group is the synthesis of biologically active natural products, especially anticancer agents, and the development of new synthetic methodologies in organic chemistry. We are also working on new methods for conjugating small-molecule drugs with biocompatible polymers for drug delivery.

The role of RUNX2 in metastatic breast and prostate cancer.

The study of normal and malignant haematopoiesis.

Pathology of gastro-intestinal and liver disease, especially cancer.

Translational research focused on novel blood, imaging and physical biomarkers of pleural malignancy, particularly Mesothelioma, and Lung Cancer. Our imaging research is centred around Magnetic Resonance Imaging. Clinical trial portfolio includes studies in diagnostics, imaging, intra-pleural therapy and pleurodesis. Additional areas of interest include Interventional Pulmonology.

The control and mechanisms of actin assembly in various normal and cancer cells.

The abnormalities of stem cell self-renewal and bone marrow microenvironment that develop in myeloid leukaemias.

Upper GI surgery and pancreaticobiliary disease.

Use of novel inducible models of intestinal tumourigenesis to study the functions of specific tumour suppressor genes.

CENTRE LEAD

We develop mitochondria-targeted probes for understanding the role of this metabolic and signalling hub in cancer. The probes include sensors, fluorophores and photo-activated and ROS-activated prodrugs.

Optimising the use of chemotherapy in prostate cancer.

Research in the Liskamp group is directed towards the creation of molecules that can be used to obtain insights into diseases such as infections and cancer, which may also lead to new approaches for their treatment.

The development and utility of novel PET/SPECT radiopharmaceuticals in both clinical and preclinical research studies.

Using state-of-the-art mass spectrometry and quantitative proteomics to study the complex molecular mechanisms regulating endothelial cells during angiogenesis.

The molecular and cellular changes that occur during mammary gland development and how these are deregulated in breast cancer.

The role of autophagy in disease persistence and drug resistance in CML.